Literature DB >> 21285904

Nephrotoxicity--what do we know and what don't we know?

Roderick Skinner1.   

Abstract

Nephrotoxicity is the development of functional or structural kidney damage after exposure to one or more of a wide variety of drugs, other treatments or exogenous toxins, and may lead to a variety of functional consequences and structural lesions. Nephrotoxicity is important as it may occur in a substantial proportion of children treated with certain drugs and occasionally lead to severe renal impairment that may prevent the delivery of optimal anticancer treatment and/or reduce the quality of life of long-term survivors. This article describes what is currently known about nephrotoxicity occurring in children treated for malignancy by summarizing published information about the clinical characteristics and long-term outcome of, and the risk factors for the development of, ifosfamide and platinum-induced renal toxicity. Published guidelines for the evaluation and surveillance of nephrotoxicity, and the still incomplete understanding of its pathogenesis, are also outlined. Many gaps in our knowledge of nephrotoxicity are highlighted, including the lack of detailed knowledge about its overall incidence and very long-term impact, the nephrotoxic potential of new drugs, the efficacy of surveillance protocols, the relevance of proteinuria as a component of nephrotoxicity, and our current inability to reliably predict or prevent many episodes of nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21285904     DOI: 10.1097/MPH.0b013e3181f8cac0

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

Review 1.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data.

Authors:  Penny Whiting; Kate Birnie; Jonathan A C Sterne; Catherine Jameson; Rod Skinner; Bob Phillips
Journal:  Support Care Cancer       Date:  2017-12-06       Impact factor: 3.603

3.  Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma.

Authors:  Jeremy M Sharib; Jobin Cyrus; Andrew Horvai; Florette K Gray Hazard; John Neuhaus; Katherine K Matthay; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2011-12-16       Impact factor: 3.167

4.  Long-term nephrotoxicity in adult survivors of childhood cancer.

Authors:  Ilona A Dekkers; Karin Blijdorp; Karlien Cransberg; Saskia M Pluijm; Rob Pieters; Sebastian J Neggers; Marry M van den Heuvel-Eibrink
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

5.  Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

Authors:  Darren R Feldman; Ilya Glezerman; Sujata Patil; Lindsay Van Alstine; Dean F Bajorin; Patricia Fischer; Amanad Hughes; Joel Sheinfeld; Manjit Bains; Lilian Reich; Kaitlin Woo; Sergio Giralt; George J Bosl; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2015-05-16       Impact factor: 2.872

6.  Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine.

Authors:  Sho Nishikawa; Naoki Takahashi; Yudai Nishikawa; Seiji Yokoi; Sayu Morita; Yuki Shimamoto; Sayumi Sakashita; Kazuhisa Nishimori; Mamiko Kobayashi; Sachiko Fukushima; Daisuke Mikami; Hideki Kimura; Kenji Kasuno; Hironobu Naiki; Masayuki Iwano
Journal:  CEN Case Rep       Date:  2022-06-24

7.  Yield of Urinalysis Screening in Pediatric Cancer Survivors.

Authors:  Matthew D Ramirez; Ann C Mertens; Natia Esiashvili; Lillian R Meacham; Karen Wasilewski-Masker
Journal:  Pediatr Blood Cancer       Date:  2016-01-21       Impact factor: 3.167

Review 8.  [Delayed effects of oncological therapy].

Authors:  H Biersack; G Brabant
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

Review 9.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities.

Authors:  Leslie L Robison; Melissa M Hudson
Journal:  Nat Rev Cancer       Date:  2013-12-05       Impact factor: 60.716

10.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.